Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bimatoprost 1% Formulation A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| All Participants | EXPERIMENTAL | Bimatoprost 1% Formulation A solution applied to the left side of the scalp and trunk area and Bimatoprost 1% Formulation B solution applied to the right side of the scalp and trunk area once daily for 14 days. |
| Name | Type | Description |
|---|---|---|
| Bimatoprost 1% Formulation A | DRUG | Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days. |
| Bimatoprost 1% Formulation B | DRUG | Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days. |
Inclusion Criteria: -Patients with mild to moderate Androgenetic Alopecia of the vertex area of the scalp. Exclusion Criteria: * Patients with uncontrolled systemic disease * History of significant cardiovascular disease * Scarring disease, infection, or abnormality of the scalp or hair shaft or ...
Bimatoprost 1% Formulation A is an investigational small molecule developed by AbbVie Inc. (ticker ABBV) for androgenetic alopecia, a form of hair loss. It is a topical formulation applied to the scalp and is in Phase 1 clinical development. It has not been approved by the FDA.
Bimatoprost 1% Formulation A is being studied for androgenetic alopecia, a common form of hair loss. The development program focuses on scalp application in male patients with this condition. It is investigational and has not been approved for any indication.
Bimatoprost 1% Formulation A targets PTGFR, the prostaglandin F receptor, and acts as an agonist at this receptor. This receptor activity is the basis for its development as a topical treatment for androgenetic alopecia.
Bimatoprost 1% Formulation A is developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is the sponsor of the clinical program evaluating this topical formulation for androgenetic alopecia.
Bimatoprost 1% Formulation A is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program has completed one trial, with no active trials currently listed.
Bimatoprost 1% Formulation A has been evaluated in one completed Phase 1 trial, NCT02848300, titled Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia. The trial enrolled 11 male participants in the United States and is now completed.